50 results on '"Hugosson, Jonas"'
Search Results
2. Prostate Cancers in the Prostate-specific Antigen Interval of 1.8–3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial
Catalog
Books, media, physical & digital resources
3. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men
4. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium
5. The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the Göteborg-1 Prostate Cancer Screening Trial
6. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts
7. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
8. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
9. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium
10. Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial
11. Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial
12. Screening for Prostate Cancer Starting at Age 50–54 Years. A Population-based Cohort Study
13. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial
14. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial
15. Corrigendum to “Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial” [Eur Urol (2022)]
16. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial
17. Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort
18. Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
19. Outcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed Expectantly
20. The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers
21. Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio
22. Follow-Up of Men with Elevated Prostate-Specific Antigen and One Set of Benign Biopsies at Prostate Cancer Screening
23. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts
24. Cryosurgical Ablation of the Prostate: 5-Year Follow-up of a Prospective Study
25. Corrigendum re: “Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial” [Eur Urol 2015;68:216–25]
26. Corrigendum re: “Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial” [Eur Urol 2016;70:566–73]
27. Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol 2016;70:767–8
28. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer
29. Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Göteborg Randomized Population-based Prostate Cancer Screening Trial
30. Corrigendum to “Incidence of Prostate Cancer After Termination of Screening in a Population-based Randomised Screening Trial” [Eur Urol 2013;64:703–9]
31. Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial
32. Short-term Results after Robot-assisted Laparoscopic Radical Prostatectomy Compared to Open Radical Prostatectomy
33. Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review
34. Active Surveillance for Low-risk Prostate Cancer: Developments to Date
35. Degree of Preservation of the Neurovascular Bundles During Radical Prostatectomy and Urinary Continence 1 Year after Surgery
36. A Different Method of Evaluation of the ERSPC Trial Confirms That Prostate-specific Antigen Testing Has a Significant Impact on Prostate Cancer Mortality
37. Incidence of Prostate Cancer After Termination of Screening in a Population-based Randomised Screening Trial
38. Reply from Authors re: H. Ballentine Carter. Prostate-specific Antigen–Based Screening for Prostate Cancer: The Irony of It All. Eur Urol 2013;65:710–11
39. Outcome Following Active Surveillance of Men with Screen-detected Prostate Cancer. Results from the Göteborg Randomised Population-based Prostate Cancer Screening Trial
40. Long-term Outcomes Among Noncuratively Treated Men According to Prostate Cancer Risk Category in a Nationwide, Population-based Study
41. Reply from Authors re: Urs E. Studer, Peter C. Albertsen. It's Time to Change the Treatment Paradigm for Prostate Cancer! Eur Urol 2013;63:97–9
42. Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)
43. Comment on the US Preventive Services Task Force's Draft Recommendation on Screening for Prostate Cancer
44. Towards an Optimal Interval for Prostate Cancer Screening
45. Platinum Priority – Reply from Authors re: Peter C. Albertsen. The Treatment Paradigm Shifts Again on Prostate Cancer. Eur Urol 2009;55:9–11
46. Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial
47. Outcome of Laterally Directed Sextant Biopsies of the Prostate in Screened Males Aged 50–66 Years
48. Tumor Volume Is a Valid Surrogate Endpoint for Defining Clinically Significant Prostate Cancers
49. Outcome of Laterally Directed Sextant Biopsies of the Prostate in Screened Males Aged 50–66 Years
50. Population-based Screening for Prostate Cancer: Is it Time?
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.